Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 10Thoracic 3Sarcoma 3Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Myeloid 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Cilengitide × Genitourinary × Clear all
NCT00121238 2016-04-28

Cilengitide in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00103337 2013-02-28

Cilengitide in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
106 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡